Form 4: MDXG CCO Receives Significant Equity Grant

MIMEDX Group's Chief Commercial Officer, Kimberly Maersk-Moller, was granted 74,163 restricted shares and 62,068 stock options.

Summary

• Kimberly Maersk-Moller, Chief Commercial Officer of MIMEDX GROUP, INC. (MDXG), reported changes in beneficial ownership.
• On March 4, 2026, Ms. Maersk-Moller was granted 74,163 shares of common stock as restricted stock.
• These restricted shares will vest fully on the third anniversary of the grant date, contingent on her continued employment.
• Following this transaction, Ms. Maersk-Moller beneficially owns 314,637 shares of common stock.
• This total includes 3,492 shares acquired on January 30, 2026, through the MiMedx Group, Inc. Employee Stock Purchase Plan.
• Additionally, on March 4, 2026, Ms. Maersk-Moller was granted 62,068 nonqualified stock options with an exercise price of $5.1 per share.
• These stock options will vest 25% on each anniversary of the grant date, also subject to her continued employment.
• The granted stock options have an expiration date of March 3, 2033.
• Following this transaction, Ms. Maersk-Moller beneficially owns 137,862 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and alignment with shareholder interests through equity ownership, which is a standard and healthy practice.

Positives

• The equity grants align the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedules for both restricted stock and options encourage retention of key executive talent.

Future Outlook

The vesting schedules for the restricted stock and stock options indicate a long-term commitment from the Chief Commercial Officer to the company's performance and future growth, contingent on continued employment.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock and stock options, are a standard component of executive compensation packages across various industries. These grants are designed to align the interests of executives with those of shareholders by tying a significant portion of their compensation to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• Equity grants are a common practice in the biotechnology and medical device sectors, similar to companies like Integra LifeSciences (IART) or Organogenesis (ORGO), to incentivize executive performance and retention.
• The vesting schedule, with a three-year full vest for restricted stock and annual 25% vesting for options, is typical for executive compensation plans, aiming to foster long-term commitment rather than short-term gains.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of executive incentives with long-term shareholder value creation.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates broader employee benefits, though this specific filing focuses on an executive grant.

Next Steps

• Continued employment of the Chief Commercial Officer to meet vesting conditions for restricted stock and stock options.
• Future vesting events for stock options on each anniversary of the grant date (March 4th) until 2030.
• Full vesting of restricted stock on March 4, 2029.

Key Dates

Keywords

MDXG, MIMEDX GROUP, equity grant, restricted stock, stock options, executive compensation, insider transaction, Form 4